血清可溶性MHCⅠ类链相关分子A在胃癌诊断中的应用价值<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2026.04.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1209 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the significance of serum soluble MHC class Ⅰ chain-related molecule A (sMICA) level in the diagnosis of gastric cancer. 【Methods】 The differences in serum levels of sMICA, carcinoembryonic antigen (CEA), carbohydrate antigens (CA19-9, CA72-4) were compared among 92 newly diagnosed gastric cancer patients (gastric cancer group), 89 gastritis patients (gastritis group) and 86 healthy people (healthy group). The relationship between serum sMICA level and disease course in gastric cancer group was analyzed. Receiver operating characteristic (ROC) curve was drawn to analyze the clinical application value of serum sMICA level in screening and diagnosis of gastric cancer. 【Results】 The serum levels of sMICA, CEA, CA19-9 and CA72-4 in the gastric cancer group were higher than those in the gastritis group and the healthy group, and the levels of all indicators in the gastritis group were higher than those in the healthy group, with statistically significant differences (P<0.05). The serum sMICA level in gastric cancer patients with different stages and different degrees of metastasis gradually increased with the progression of the disease (P<0.05), but there was no significant correlation with the degree of differentiation of gastric cancer patients (P>0.05). The combined detection of sMICA+CEA+CA19-9+CA72-4 had high diagnostic efficacy for gastric cancer patients (P<0.05). 【Conclusion】 The detection of serum sMICA level is helpful for the screening and diagnosis of gastric cancer, and can be used as a biomarker for the clinical diagnosis and treatment of gastric cancer.

Key words： Stomach Neoplasms Histocompatibility Antigens Class Ⅰ Diagnosis

Received: 14 November 2025

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Man
	XU Quanxiao
	YAO Chuanshan
	ZHANG Like
	LIANG Lingxia
	ZHAO Xulin

Cite this article:

ZHANG Man,XU Quanxiao,YAO Chuanshan, et al. Application of Serum Soluble MHC Class Ⅰ Chain-Related Molecule A in Clinical Diagnosis of Gastric Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 544-547.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.04.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I4/544

[1] 陈雪茹,钟晨,张丽翠,等. 血浆D-二聚体与胃癌临床病理特征、预后的关系分析[J].国际检验医学杂志,2024,45(18):2281-2285.
[2] YOON S E, PARK S, CHO J,et al. The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma[J].Front Oncol,2023,16(13):1194315.
[3] MARIN M L C, RACHED M R, MONTEIRO S M,et al. Soluble MICA in endometriosis pathophysiology: Impairs NK cell degranulation and effector functions[J].Am J Reprod Immunol,2024,91(3):13830.
[4] GUO F F,DU N W, WEN X,et al. CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A[J].Cell Mol Life Sci,2024,81(1):307.
[5] ARAI J, OTOYAMA Y, FUJITA K I,et al. Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer[J].BMC Cancer,2022,22(1):428.
[6] 《胃癌中西医结合诊疗指南》标准化项目组. 胃癌中西医结合诊疗指南(2023年)[J].中国中西医结合杂志,2024,44(3):261-272.
[7] 徐泽宽,李铮,徐皓. 从2023年国际胃癌大会看胃癌外科治疗进展与发展趋势[J].中国实用外科杂志,2023,43(9):971-974.
[8] VELA-OJEDA J, OLIVAS-BEJARANO A C, MONTIEL-CERVANTES L A,et al. Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma[J].Eur J Haematol,2024,113(3):321-329.
[9] SELLER A, TEGELER C M, MAUERMANN J,et al. Soluble NKG2DLs are elevated in breast cancer patients and associate with disease outcome[J].Int J Mol Sci,2024,25(7):4126.
[10] OLIVAS-BEJARANO A C , MONTIEL-CERVANTES L A , CARMEN PEREZ-RETIGUIN F D,et al. Lymphocyte subsets and soluble forms of MIC-A and MIC-B are prognostic factors in non-Hodgkin lymphoma patients[J].Ann Hematol,2024,103(4):1317-1325.
[11] LOPEZ-MONTAÑO M, JIMENEZ-ORTEGA L, CRUZ-HERNANDEZ T R ,et al. Significant increase in MIC-A and MIC-B and soluble MIC-A and MIC-B in canine lymphomas[J].Vet Immunol Immunopathol,2023,264(1):110647.
[12] PACHANI P A, GODBOLE R R, KSHERSAGAR J,et al. A comparative study of smica in various body fluids of diagnosed cervical cancer patients and healthy women[J].Obstet Gynecol Sci,2022,65(1):37-45.
[13] TCHACROME I, ZHU Q, SALEH M A,et al. Diseases association with the polymorphic major histocompatibility complex class I related chain a: MICA gene[J].Transpl Immunol,2022,75(3):101665.
[14] IVANOVA M, TSVETKOVA G, LESSICHKOVA S,et al. Exploration of the role of NKG2D ligands MICA and MICB in JAK2 V617F-positive myeloproliferative neoplasms[J].HLA,2023,102(2):168-178.